Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Leukemia

Free Subscription 20.04.2026 2 Am J Hematol 2 Ann Hematol 1 Biochem Biophys Res Commun 1 Blood 3 Bone Marrow Transplant 10 Br J Haematol 2 Cancer 1 Eur J Haematol 2 Int J Hematol 3 Leuk Lymphoma 8 Leuk Res 5 Leukemia 1 Oncol Rep 1 Proc Natl Acad Sci U S A

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Hematol

1. PASIC I, Lipton JH
   The Role of Allogeneic Hematopoietic Cell Transplantation in the Management of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors.
   Am J Hematol. 2026 Apr 15. doi: 10.1002/ajh.70330.
   PubMed         Abstract available
   
   
2. TSIRIGOTIS P, Garofalaki M, Lazana I, Liga M, et al
   Real-World Outcomes in NPM1-Mutated Acute Myeloid Leukemia: The Impact of Measurable Residual Disease on Disease Relapse.
   Am J Hematol. 2026 Apr 10. doi: 10.1002/ajh.70322.
   PubMed         Abstract available
   
   

   
   Ann Hematol

3. CANNELLA L, Venditti A, Palmieri R, Puglia S, et al
   Health-related quality of life of patients with acute myeloid leukemia and myelodysplastic syndromes/neoplasms treated with decitabine: a systematic literature review.
   Ann Hematol. 2026;105:249.
   PubMed        
   
   
4. FRIGENI M, Algarotti A, Salmoiraghi S, Belotti C, et al
   Avapritinib for targeting KIT D816V-mutated acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplant with extramedullary and central nervous system involvement.
   Ann Hematol. 2026;105:238.
   PubMed         Abstract available
   
   

   
   Biochem Biophys Res Commun

5. OPYDO M, Wojtaszek M, Mosurek A, Burczyk G, et al
   Targeting BCL-2 and PI3K signaling pathways enhances cytotoxicity of gemtuzumab ozogamicin against acute myeloid leukemia cells.
   Biochem Biophys Res Commun. 2026;817:153752.
   PubMed         Abstract available
   
   

   
   Blood

6. ZENT CS, Tiacci E, Kreitman RJ, Tadmor T, et al
   Updated consensus guidelines for the diagnosis and management of patients with hairy cell leukemia (HCL) and HCL-variant.
   Blood. 2026 Apr 14:blood.2025032757. doi: 10.1182/blood.2025032757.
   PubMed         Abstract available
   
   

   
   Bone Marrow Transplant

7. JESTIN M, Maury S, Huynh A, Forcade E, et al
   Impact of stem cell source in HLA-matched hematopoietic stem cell transplant for acute lymphoblastic leukemia in first complete remission: a study from the GRAALL and the SFGM-TC.
   Bone Marrow Transplant. 2026 Apr 16. doi: 10.1038/s41409-026-02837.
   PubMed        
   
   
8. FOURMONT AM, Beauvais D, Balsat M, Maertens J, et al
   Alternative versus matched unrelated donor in adolescents and young adults transplanted for acute myeloid leukemia in first complete remission: A report from the SFGM-TC.
   Bone Marrow Transplant. 2026 Apr 13. doi: 10.1038/s41409-026-02853.
   PubMed        
   
   
9. KANELLOPOULOS A, Koster L, de Lavallade H, Orti G, et al
   Management of tyrosine kinase inhibitors and donor lymphocyte infusions post transplantation for chronic myeloid leukemia: a survey of contemporary practice on behalf of the chronic malignancies working party of the EBMT.
   Bone Marrow Transplant. 2026 Apr 10. doi: 10.1038/s41409-026-02862.
   PubMed         Abstract available
   
   

   
   Br J Haematol

10. CRESPO-GARCIA E, Quero-Dotor C, Noguera-Castells A, Sancho-Vila L, et al
    Epigenetic silencing and pharmacological inhibition of EIF5A2 foster venetoclax sensitivity in acute myeloid leukaemia.
    Br J Haematol. 2026;208:1437-1442.
    PubMed         Abstract available
    
    
11. DAI X, Wu Z, Zhang W, Chen S, et al
    DHCR7 drives AML development through the IL6/JAK2/STAT3 signalling pathway.
    Br J Haematol. 2026;208:1263-1277.
    PubMed         Abstract available
    
    
12. LEE YW, Chiang CJ, Lin YC, Tzeng HE, et al
    Second primary malignancies in Asian chronic lymphocytic leukaemia patients: A Taiwan Cancer Registry Study.
    Br J Haematol. 2026;208:1278-1286.
    PubMed         Abstract available
    
    
13. MONAGHAN L, Bunschoten RP, Bittencourt-Silvestre J, Park T, et al
    Selective small molecule targeting of KDM4 as a therapeutic strategy to reduce proliferation of acute myeloid leukaemia.
    Br J Haematol. 2026;208:1240-1251.
    PubMed         Abstract available
    
    
14. BIDET A, Laharanne E, Dos Santos M, De Grande AC, et al
    Optical genome mapping detects cryptic high-risk and targetable abnormalities in adult AML.
    Br J Haematol. 2026;208:1232-1239.
    PubMed         Abstract available
    
    
15. KOMORI T, Kawai T, Okuno Y, Tsujimoto S, et al
    Identification of cellular hierarchy in paediatric acute myeloid leukaemia: The Japan Children's Cancer Group trial (JCCG AML-12).
    Br J Haematol. 2026;208:1252-1262.
    PubMed         Abstract available
    
    
16. TIAN Z, Deng Z, Han F, Yu L, et al
    An AI-based IHC quantification technique for assisting in the differentiation of MCL from CLL/SLL.
    Br J Haematol. 2026;208:1287-1295.
    PubMed         Abstract available
    
    
17. ERIKSEN JVN, de Pietri S, Rathe M, Hasle H, et al
    Plasma calprotectin to assess susceptibility to bloodstream infections during paediatric acute lymphoblastic leukaemia induction treatment.
    Br J Haematol. 2026;208:1339-1346.
    PubMed         Abstract available
    
    
18. DESAI N, Althobaiti M, Chen C, Al-Shaibani E, et al
    Improved early transplant outcomes with reduced-dose PTCy and low-dose ATG in matched unrelated donor allogeneic transplantation for acute myeloid leukaemia.
    Br J Haematol. 2026;208:1359-1368.
    PubMed         Abstract available
    
    
19. JEBARAJ BMC, Stilgenbauer S
    Short and complex-Telomeres and genomes in CLL.
    Br J Haematol. 2026;208:1503-1504.
    PubMed         Abstract available
    
    

    
    Cancer

20. COSTE A, Sritharan N, Lok A, Tomowiak C, et al
    Factors influencing front line treatment of chronic lymphocytic leukemia: A French real-world study.
    Cancer. 2026;132:e70406.
    PubMed         Abstract available
    
    
21. ALONSO-DOMINGUEZ JM, Castano-Bonilla T, Gil C, Serrano-Lopez J, et al
    Reassessing adverse prognosis of acute myeloid leukemia harboring BCR::ABL1 in the era of tyrosine kinase inhibitors: A real-world analysis from the PETHEMA registry.
    Cancer. 2026;132:e70353.
    PubMed         Abstract available
    
    

    
    Eur J Haematol

22. CASERTA S, Martino EA, Lofaro D, Vigna E, et al
    First-Line Treatment of IGHV-Unmutated Chronic Lymphocytic Leukemia: A Network Meta-Analysis of Targeted and Chemoimmunotherapy Regimens.
    Eur J Haematol. 2026 Apr 14. doi: 10.1111/ejh.70191.
    PubMed         Abstract available
    
    

    
    Int J Hematol

23. HIRAMATSU Y, Urata S, Ishikawa T, Yamauchi T, et al
    A narrative review of mutant isocitrate dehydrogenase AML in Japan based on experience with ivosidenib in AGILE.
    Int J Hematol. 2026;123:509-515.
    PubMed         Abstract available
    
    
24. SHICHIJO T, Yasunaga JI
    Viral-driven oncogenesis in T/NK-cell lymphomas: parallels and divergences between HTLV-1 and EBV.
    Int J Hematol. 2026;123:476-486.
    PubMed         Abstract available
    
    

    
    Leuk Lymphoma

25. MARKOSIAN C, Buckley CW, Chai-Ho W, Schiller GJ, et al
    Differential responses to sequential menin inhibitor therapy for acute leukemia underscore the complexities of acquired resistance.
    Leuk Lymphoma. 2026 Apr 15:1-4. doi: 10.1080/10428194.2026.2656727.
    PubMed        
    
    
26. MAJRASHI A, Shantsila A, Gue YX, Williams S, et al
    Effect of age and sex on cardiovascular outcomes among patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors: a propensity matched analysis.
    Leuk Lymphoma. 2026 Apr 11:1-11. doi: 10.1080/10428194.2026.2653123.
    PubMed         Abstract available
    
    
27. MICHAELS-IGBOKWE C, Lu H, Winfree KB, Bhandari NR, et al
    Treatment choice for chronic lymphocytic leukemia after covalent BTKi therapy: a patient and oncologist preference study.
    Leuk Lymphoma. 2026 Apr 10:1-13. doi: 10.1080/10428194.2026.2648867.
    PubMed         Abstract available
    
    

    
    Leuk Res

28. ZHANG X, Bustamante J, Stefani H, Lee H, et al
    Development and temporal validation of an interpretable point score for in-hospital mortality in CLL/SLL using the U.S. National Inpatient Sample, 2016-2022.
    Leuk Res. 2026;164:108199.
    PubMed         Abstract available
    
    
29. YAMAMOTO J, Yamamoto H, Watanabe O, Kuno M, et al
    Outcomes and prognostic factors of hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia and central nervous system involvement.
    Leuk Res. 2026;165:108226.
    PubMed         Abstract available
    
    
30. SCHUTTE D, Call EM, Furstenau M, Beckmann L, et al
    Retrospective, single-center analysis of second allogeneic stem cell transplantation versus non-transplant regimens for acute myeloid leukemia patients with relapse after first transplantation.
    Leuk Res. 2026;165:108228.
    PubMed         Abstract available
    
    
31. HOU R, An L, Guan H, Lei X, et al
    Systemic evaluation for extramedullary disease and treatment outcomes in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
    Leuk Res. 2026;165:108231.
    PubMed         Abstract available
    
    
32. SALTER B, Ge S, Berg T, Garcia-Horton A, et al
    Efficacy of hypomethylating agents in combination with venetoclax in relapsed/refractory acute myeloid leukemia: A systematic review and meta-analysis.
    Leuk Res. 2026;165:108227.
    PubMed         Abstract available
    
    
33. MUKAE J, Sadato D, Toya T, Hirama C, et al
    Chronic neutrophilic leukemia with transformation to B-lymphoblastic leukemia.
    Leuk Res. 2026;166:108229.
    PubMed        
    
    
34. KIR S, Abdullayeva N, Yilmazer A, Saydam G, et al
    Clinical use and adverse effects of tyrosine kinase inhibitors in patients with chronic myeloid leukemia: The role of comorbidities.
    Leuk Res. 2026;166:108235.
    PubMed         Abstract available
    
    
35. YUAN F, Zhao X, Lin X, Wang J, et al
    Risk factors and fluid management in tumor lysis syndrome of acute myeloid leukemia: A retrospective study.
    Leuk Res. 2026;166:108232.
    PubMed         Abstract available
    
    

    
    Leukemia

36. CHIN KK, Abdul-Hay M, Shukla M, Geyer MB, et al
    Overcoming MEN1-mediated resistance with menin inhibitor switching in KMT2A-rearranged acute myeloid leukemia.
    Leukemia. 2026 Apr 10. doi: 10.1038/s41375-026-02959.
    PubMed        
    
    
37. ZHOU C, Bian S, Pang J, Bian H, et al
    mRNA vaccination targeting AML1::ETO fusion gene eliminates leukemia cells via activating T cells.
    Leukemia. 2026 Apr 10. doi: 10.1038/s41375-026-02940.
    PubMed        
    
    
38. BHATIA S, Hageman L, Chen Y, Wadhwa A, et al
    Adherence-enhancing intervention and relapse in childhood acute lymphoblastic leukemia: results from the Children's Oncology Group randomized trial ACCL1033.
    Leukemia. 2026 Apr 13. doi: 10.1038/s41375-026-02951.
    PubMed        
    
    
39. NEELAMRAJU Y, Rapaport F, Gandara JA, Paudel BB, et al
    Elevated levels of TNF and its targets characterize better-risk older acute myeloid leukemia patients.
    Leukemia. 2026 Apr 13. doi: 10.1038/s41375-026-02954.
    PubMed        
    
    
40. KANDARPA M, Peterson LF, Potu H, Ramappan M, et al
    Activity of PROTAC MDM2 degrader in primary leukemia cells and PDX models.
    Leukemia. 2026 Apr 15. doi: 10.1038/s41375-026-02957.
    PubMed         Abstract available
    
    

    
    Oncol Rep

41. CHENG H, Zheng G, Yang Y, Xu C, et al
    Incorporating artificial intelligence into morphological diagnosis of acute leukemias: Current landscape, challenges and prospects (Review).
    Oncol Rep. 2026;55:115.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

42. WANG Y, Xie J, Pasca S, Popoli M, et al
    A plasma-based DNA test for quantification of disease burden in acute myeloid leukemia patients undergoing bone marrow transplantation.
    Proc Natl Acad Sci U S A. 2026;123:e2537987123.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum